SCHEMBL6980724

SCHEMBL6980724

CCCCc1ccc(Sc2nc3ccc(S(=O)(=O)N[C@@H](C(=O)O)C(C)C)cc3s2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
MMP2 P08253 2/20 0.48
MMP9 P14780 2/20 0.48
ALOX15 P16050 1/20 0.46
MEN1 O00255 1/20 0.45
CYP2C9 P11712 1/20 0.45
KMT2A Q03164 1/20 0.45
MMP12 P39900 6/20 0.45
MMP13 P45452 4/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
TP53 P04637 1/20 0.42
ADAMTS4 O75173 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5755143 0.86 ALDH1A1 (0.56) ALDH1A1GAAMMP2MMP9ALOX15
SCHEMBL5757303 0.86 MMP13 (0.55) ALDH1A1GAAMMP2MMP9ALOX15
SCHEMBL5757712 0.86 MMP13 (0.54) ALDH1A1GAAMMP2MMP9ALOX15
SCHEMBL5756197 0.86 MMP13 (0.54) ALDH1A1GAAMMP2MMP9ALOX15
SCHEMBL5758777 0.86 HTT (0.54) ALDH1A1GAAMMP2MMP9ALOX15
SCHEMBL6966735 0.84 MMP13 (0.55) MMP2MMP9MEN1CYP2C9KMT2A
SCHEMBL5754971 0.84 ALOX15 (0.50) ALDH1A1GAAALOX15MEN1CYP2C9
SCHEMBL5756700 0.83 ALOX15 (0.49) ALDH1A1GAAALOX15MEN1CYP2C9
SCHEMBL5756480 0.82 PPARG (0.49) ALDH1A1GAAALOX15MEN1CYP2C9
SCHEMBL5757384 0.82 PPARG (0.49) ALDH1A1GAAALOX15MEN1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 ALDH1A1 311/4885GAA 134/4885MMP2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.